Medela LLC reported on Tuesday the receipt of a group purchasing contract for its Lactation Care, including breast pumps, from Vizient Inc, health care company.
Headquartered in Switzerland, Medela will provide research-based breast milk feeding solutions to support a mother's ability to provide the life-giving benefits of breast milk to her baby.
This agreement is in addition to Vizient prior contracts for Medela's full product portfolio from their Human Milk business unit, including enteral feeding and accessories.
Vizient's diverse membership base includes academic medical centres, paediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers and represents approximately $100 billion in annual purchasing volume.
Founded in 1961, Medela concentrates on two business units: Human Milk, which provides research-based breast milk feeding solutions as well as Healthcare, which is based on the engineering and manufacturing medical vacuum technology solutions.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA